5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Metabolite Analysis, Application (Biomarker and Drug Discovery, Toxicology, Nutrigenomics, Personalized Medicine, and Other Applications), and Geography
Fastest Growing Market:
The metabolomics market was valued at USD 1,637.43 million in 2018, and is expected to reach USD 3,565.82 million by 2024. It is estimated to register a CAGR of 13.85%, during the forecast period (2019-2024).
The high growth rate for this market is primarily due to its high demand in scientific communities for better analysis of diseases, biological processes, and growing applications in healthcare. There are a growing number of research universities collaborating with companies in developed markets, which use a combination of separation and detection techniques, such as GC-MS, for metabolite profiling of large sets of drugs for diagnosis and treatment of several chronic diseases, like diabetes mellitus. These researches are often recognized at the national level, and governments with private equity partners provide funds for more research toward drug discovery, biomarkers, and other related studies.
Metabolomics represent a systematic study of unique chemical processes inside the cells, which involve metabolites. The collection of entire metabolites in a biological cell, tissue, organ, or organism is called metabolome, which are the end products of cellular processes. In the past one decade, the scientific communities across the world have been integrating proteomic, transcriptomic, and metabolomic information, which helps in the early analysis of any chronic genetic or infectious diseases. These are funded by several private and public funding, which helps in the growth of the metabolomics market.
|By Metabolite Analysis|
|Bioinformatics Tools and Database|
|Biomarker and Drug Discovery|
Report scope can be customized per your requirements. Click here.
The biomarket and drug discovery segment, under application, is projected to record a CAGR of 13.4%, over the forecast period.
Metabolomics focus mainly on profiling small-molecule metabolites (metabolic profiling), and differ from genomics and proteomics, which characterize the profiles of genes and proteins, respectively. Additionally, biomarkers are the objective and quantitatively-measurable indicators of biological or pathogenic processes. Both metabolomics and biomarkers are progressively used in drug discovery and development, managing disease progression, especially for the personalized or precision medicine. Metabolomics and biomarkers are likely to advance the drug development and personalized therapy in the future, mainly in highly demanding disease areas, such as cardiovascular and metabolic diseases, cancer, mental health, and other infectious diseases. The increasing challenges faced by the pharmaceutical industry, such as dwindling discovery pipelines, limited budget sanctioned for a particular R&D, increasing regulatory control, significant gaps in the future drug markets, are expected to drive growth of the market.
To understand key trends, Download Sample Report
North America is expected to dominate the market, over other regions, throughout the forecast period. The presence of high per capita healthcare expenditure, increasing adoption rate of healthcare technology, well-established direct sales channel across the region, and continuous boost to small and mid-sized metabolomics-oriented research communities and companies, globally, from the National Institutes of Health (NIH) program, help in the growth of metabolomics business.
To understand geography trends, Download Sample Report.
The metabolomics market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. The major global companies, such as Thermofisher, Bruker Corporation, and Agilent Technologies, are increasing collaboration with educational societies and research communities, funding them for more research with combination, separation, and detection technique licenses. With specific requirement to metabolite research, the HPLC and UPLC are increasingly preferred over other techniques for its most versatile separation method. Several pharmaceutical companies prefer research institutes for characterizing toxicological studies, to develop new drugs against infectious diseases. The technical advancements and combination with MS and NMR are being rapidly adopted, globally. These segments, thus, primarily drive the market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Personalized Medicines
4.2.2 High Investments by Public and Private Sectors in the Field of Metabolomics
4.2.3 Rising Need for Early and Accurate Diagnosis of Diseases
4.3 Market Restraints
4.3.1 High Cost of Tools and Instruments
4.3.2 Lack of Skilled Professionals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Metabolite Analysis
5.1.1 Analytical Techniques
18.104.22.168 Separation Techniques
22.214.171.124.1 Liquid Chromatography
126.96.36.199.2 Gas Chromatography
188.8.131.52.3 Capillary Electrophoresis
184.108.40.206 Detection Techniques
220.127.116.11.1 Mass Spectrometry
18.104.22.168.2 Nuclear Magnetic Resonance Spectroscopy
22.214.171.124.3 Other Detection Techniques
5.1.2 Bioinformatics Tools and Database
5.2 By Application
5.2.1 Biomarker and Drug Discovery
5.2.4 Personalized Medicine
5.2.5 Other Applications
5.3.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
5.3.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Bruker Corporation
6.1.4 Danaher Corporation (SCIEX)
6.1.5 LECO Corporation
6.1.6 Shimadzu Corporation
6.1.7 Thermo Fisher Scientific
6.1.8 Waters Corporation
6.1.9 PerkinElmer Inc.
6.1.10 Kore Technology Limited
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments